产品
编 号：F750836
分子式：C18H16FN3O3
分子量：341.34
分子式：C18H16FN3O3
分子量：341.34
产品类型
规格
价格
是否有货
结构图
CAS No: 2276711-87-4
产品详情
生物活性：
Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC50 value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable agent-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model.
体内研究：
Xanthine oxidase-IN-5 (compound 9m) shows potent hypouricemic effects at an oral dose of 20 mg/kg in a rat hyperuricemia model induced by potassium oxonate.Animal Model:Potassium oxonate-induced hyperuricemic rat model
Dosage:20 mg/kg
Administration:PO; single (measured serum uric acid after 0.5 - 8 hours)
Result:Showed potent hypouricemic effects at an oral dose of 20 mg/kg in a rat hyperuricemia model induced by potassium oxonate.
Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC50 value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable agent-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model.
体内研究：
Xanthine oxidase-IN-5 (compound 9m) shows potent hypouricemic effects at an oral dose of 20 mg/kg in a rat hyperuricemia model induced by potassium oxonate.Animal Model:Potassium oxonate-induced hyperuricemic rat model
Dosage:20 mg/kg
Administration:PO; single (measured serum uric acid after 0.5 - 8 hours)
Result:Showed potent hypouricemic effects at an oral dose of 20 mg/kg in a rat hyperuricemia model induced by potassium oxonate.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备